We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Novel Blood-Based Assay to Aid in Early Diagnosis and Intervention for Alzheimer's

By LabMedica International staff writers
Posted on 19 Jul 2023

Recent FDA approvals have marked significant progress in Alzheimer's disease treatments, paving the way for a new generation of therapies. More...

However, the challenge of early Alzheimer's diagnosis remains a key obstacle to the widespread use and accessibility of these treatments. That could now change with a novel, proprietary assay for the blood-based measurement of a highly accurate, diagnostic biomarker for Alzheimer's disease.

ALZpathDx, a proprietary assay developed by ALZpath (Carlsbad, CA, USA), measures phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer's disease. The assay quantifies pTau217 in blood, providing insightful data about brain activity. The biomarker can identify Alzheimer's key indicators in the brain before cognitive symptoms appear. However, the availability of pTau217 tests for research and clinical use is limited. Thus, increasing access to this accurate Alzheimer's disease biomarker is essential for broader evaluation and implementation of Alzheimer's blood tests. Non-invasive tau blood tests like ALZpathDx, capable of accurately measuring specific tau protein levels in the blood, could positively affect patient outcomes through early diagnosis and intervention for Alzheimer's. The assay is conducted on the Quanterix Simoa HD-X immunoassay analyzer.

ALZpath has recently obtained funding from the Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator to expedite ALZpathDx's clinical availability as a laboratory-developed test (LDT). This financial support will allow ALZpath to continue gathering clinical evidence and launch an LDT version of the assay, crucial for timely Alzheimer's detection. Currently, the ALZpath pTau217 assay is available for research use only (RUO) through Quanterix, both as a kit and for services in the Quanterix Accelerator laboratory.

"The Alzheimer's Drug Discovery Foundation has had a transformative impact in advancing the understanding, diagnosis and treatment of Alzheimer's disease," said ALZpath Chief Scientific Officer and principal investigator, Dr. Andreas Jeromin. "Building on that legacy, and with their support, we can now continue expanding our efforts with the goal of ensuring broad clinical availability of ALZpathDx, which will be critical in facilitating timely and accurate detection, as well as providing scalable access to disease-modifying treatments for people living with Alzheimer's."

Related Links:
ALZpath 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.